Five Buying Opportunities From Our Upcoming Stocks Forum
Management from these undervalued wide- and narrow-moat stocks will be presenting at our fifth annual event.
Management from these undervalued wide- and narrow-moat stocks will be presenting at our fifth annual event.
In an uncertain and volatile economic environment, rather than shying away from investing, we at Morningstar think the market provides a wide array of promising wide- and narrow-moat companies for investors to consider. Many of these companies will be speaking at our 5th Annual Stocks Forum in early November. While we wait to hear from several C-level employees, we'd like to preview some of the participating firms that look attractive to us today.
Before delving into the companies, it is important to understand Morningstar's investment approach. We think buying wide- or narrow-moat stocks at a discount is a great long-term strategy. You can own a piece of a business with competitive advantages that will allow the firm to earn excess returns on capital well into the future, while benefiting from additional price appreciation as the market recognizes that underlying value.
Behind each of these companies' moats is a management team. Individual investors attending the 2010 forum will get the rare opportunity of direct access to a company's senior management. Some of these managers, including former Morningstar CEOs of the Year Will Oberton of Fastenal (FAST) and Robert Silberman of Strayer Education (STRA), will discuss how they deal with the constant pressure for short-term results while also managing the long-term strategies that make their businesses fundamentally attractive. For those who can't attend the event, Morningstar.com will offer on-the-spot blog coverage followed up by video interviews with attendees and presenters.
While we think any of the 31 participating companies should be on the radar of long-term investors, below we highlight several of those firms that are currently trading at a discount to what we think they are worth.
General Electric (GE)
Morningstar Rating: 5 stars | Dividend Yield: 2.9%
General Electric positions itself to be a leader in all markets in which it competes. After shedding underperforming businesses during the past few years, the firm has energy infrastructure square in its sights. We believe that GE will emerge as a leader in the power infrastructure market, which will be the backbone for the firm's growth.
Range Resources (RRC)
Morningstar Rating: 5 stars | Dividend Yield: 0.43%
Range Resources is a first-mover into the potentially prodigious Marcellus Shale in the Appalachian Basin. With about 1 million net acres in the play, Range stands to extract significant value from the Marcellus during the next several years. Due to its early entry into the play, Range's lease terms are very favorable, which, coupled with the attractive cost structure and production profile of individual wells, make the play very economical with natural gas prices as low as $4 per mcf. Range's low corporate decline curve and its exposure to the Marcellus Shale reduce reinvestment risk and should translate into strong returns on capital for many years.
Pfizer (PFE)
Morningstar Rating: 5 stars | Dividend Yield: 4.2%
Pfizer's foundation remains solid, based on strong cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This unmatched heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build a wide economic moat around its business.
Myriad Genetics (MYGN)
Morningstar Rating: 4 stars | Dividend Yield: n/a
While Myriad's growth has slowed with the recession and a corresponding reduction in physician office visits, the firm's expertise in genetic analysis positions Myriad well for a rebound. The firm has established a narrow moat around BRACAnalysis, which detects genetic mutations that confer a high risk of developing breast or ovarian cancer. The pairing of diagnostic tests with cancer treatments is also an emerging trend, and we expect Myriad to directly benefit from steps to tailor cancer therapy to a patient's genetic profile. We're looking forward to hearing CEO Pete Meldrum's take on how the firm can use its strong free cash flows to encourage uptake of its newer tests, expand globally, and extend its moat.
ArcelorMittal (MT)
Morningstar Rating: 4 stars | Dividend Yield: 1.9%
ArcelorMittal is more than 3 times larger than the next-biggest steel company yet has only 8% market share. This represents further opportunity for consolidation, and the company is well-poised to take advantage when the merger and acquisition market returns, given its global reach and access to high-growth markets, expertise in developing markets, and successful M&A record. Supplying 20% of the global automotive market's steel needs, the company has become a strategic partner for many large manufacturers as a major contributor to value creation, reaffirming its importance in the global steel market.
Here is a complete list of the companies that will be presenting at the 2010 Stocks Forum:
ArcelorMittal (MT)
Market Cap: $52.2 billion
Morningstar Rating: 4 stars
AT&T (T)
Market Cap: $170.0 billion
Morningstar Rating; 3 stars
Boardwalk Pipeline Partners
Market Cap: $6.4 billion
Morningstar Rating: 2 stars
CarMax (KMX)
Market Cap: $6.2 billion
Morningstar Rating: 3 stars
China Gerui Advanced Materials Group (CHOP)
Market Cap: $272.5 million
Morningstar Rating: 4 stars
Choice Hotels International (CHH)
Market Cap: $2.2 billion
Morningstar Rating: 2 stars
CoStar Group (CSGP)
Market Cap: $1.0 billion
Morningstar Rating: 3 stars
Cullen/Frost Bankers (CFR)
Market Cap: $3.3 billion
Morningstar Rating: 3 stars
Cymer
Market Cap: $1.6 billion
Morningstar Rating: 2 stars
Fastenal (FAST)
Market Cap: $8.0 billion
Morningstar Rating: 2 stars
FedEx (FDX)
Market Cap: $27.7 billion
Morningstar Rating: 4 stars
First American Financial (FAF)
Market Cap: $1.5 billion
Morningstar Rating: 4 stars
General Electric (GE)
Market Cap: $181.3 billion
Morningstar Rating: 5 stars
General Mills (GIS)
Market Cap: $23.7 billion
Morningstar Rating: 3 stars
Gen-Probe
Market Cap: $2.4 billion
Morningstar Rating: 3 stars
Graco (GGG)
Market Cap: $2.0 billion
Morningstar Rating: 3 stars
McCormick & Company (MKC)
Market Cap: $5.6 billion
Morningstar Rating: 3 stars
McDonald's (MCD)
Market Cap: $80.6 billion
Morningstar Rating: 2 stars
Myriad Genetics (MYGN)
Market Cap: $1.6 billion
Morningstar Rating: 4 stars
Nalco Holding Company
Market Cap: $3.5 billion
Morningstar Rating: 3 stars
Parexel International
Market Cap: $1.3 billion
Morningstar Rating: 3 stars
Pfizer (PFE)
Market Cap: $139.3 billion
Morningstar Rating: 5 stars
Range Resources (RRC)
Market Cap: $6.0 billion
Morningstar Rating: 5 stars
Ritchie Bros. Auctioneers (RBA)
Market Cap: $2.2 billion
Morningstar Rating: 3 stars
Sanofi-Aventis (SNY)
Market Cap: $89.6 billion
Morningstar Rating: 4 stars
Steel Dynamics (STLD)
Market Cap: $3.1 billion
Morningstar Rating: 4 stars
Stericycle (SRCL)
Market Cap: $6.1 billion
Morningstar Rating: 3 stars
Strayer Education (STRA)
Market Cap: $2.4 billion
Morningstar Rating: 5 stars
Texas Instruments (TXN)
Market Cap: $33.5 billion
Morningstar Rating: 3 stars
United Parcel Service (UPS)
Market Cap: $67.3 billion
Morningstar Rating: 3 stars
Wipro (WIT)
Market Cap: $38.5 billion
Morningstar Rating: Under Review
Data as of Oct. 6, 2010.
Morningstar analyst Jeremy Cohen and intern Jonathan Eng contributed to this article.
Heather Brilliant has a position in the following securities mentioned above: FAF. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.